PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts

BACKGROUND: PARP inhibitors niraparib and talazoparib are FDA approved for special cases of breast cancer. PARP is an interesting repair protein which is frequently affected in cancer cells. We studied the combined action of talazoparib or niraparib with ionizing radiation in melanoma cells and heal...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Weigert, Verena, Jost, Tina, Hecht, Markus, Knippertz, Ilka, Heinzerling, Lucie, Fietkau, Rainer, Distel, Luitpold V.
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2020
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7433076/
https://ncbi.nlm.nih.gov/pubmed/32811446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07190-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires